• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

保肾治疗(NEST)小肾肿瘤:经皮冷冻消融与机器人辅助部分肾切除术比较的可行性队列嵌入式随机对照试验。

Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.

机构信息

Division of Surgery and Interventional Sciences, University College London, London, UK; Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.

Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK.

出版信息

Eur Urol. 2024 Apr;85(4):333-336. doi: 10.1016/j.eururo.2023.07.012. Epub 2023 Sep 9.

DOI:10.1016/j.eururo.2023.07.012
PMID:37684178
Abstract

There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled in the RCT. In the CRA intervention arm, 84% consented (95% confidence interval [CI] 64-95%) and 76% (95% CI 55-91%) received CRA; 100% (95% CI 86-100%) of the control arm underwent RPN. The retention rate was 90% (95% CI 79-96%) at 6 mo. In the RPN group 2/25 (8%) were converted intra-operative to radical nephrectomy. Postoperative complications (Clavien-Dindo grade 1-2) occurred in 12% of the CRA group and 29% of the RPN group. The median length of hospital stay was shorter for CRA (1 vs 2 d; p = 0.019). At 6 mo, the mean change in renal function was -5.0 ml/min/1.73 m after CRA and -5.8 ml/min/1.73 m after RPN. This study demonstrates the feasibility of a cohort-embedded RCT comparing CRA and RPN. These data can be used to inform multicentre trials on SRM management. PATIENT SUMMARY: We assessed whether patients with a small kidney tumour would consent to a trial comparing two different treatments: cryoablation (passing small needles through the skin to freeze the kidney tumour) and surgery to remove part of the kidney. We found that most patients agreed and a full trial would therefore be feasible.

摘要

目前关于小肾肿瘤(SRM)管理的高级别证据很少,因为之前的经典随机对照试验(RCT)未能达到入组目标。我们的目的是评估一项比较冷冻消融(CRA)和机器人部分肾切除术(RPN)的队列嵌入式 RCT 的招募可行性。共有 200 名患者入组该队列,其中 50 名入组 RCT。在 CRA 干预组中,84%(95%置信区间 [CI] 64-95%)同意入组,76%(95% CI 55-91%)接受了 CRA;对照组 100%(95% CI 86-100%)行 RPN。6 个月时的保留率为 90%(95% CI 79-96%)。在 RPN 组中,2/25(8%)术中转为根治性肾切除术。CRA 组和 RPN 组术后并发症(Clavien-Dindo 分级 1-2)发生率分别为 12%和 29%。CRA 组的中位住院时间较短(1 天与 2 天;p=0.019)。6 个月时,CRA 后肾功能平均变化为-5.0 ml/min/1.73 m 2 ,RPN 后为-5.8 ml/min/1.73 m 2 。本研究证明了比较 CRA 和 RPN 的队列嵌入式 RCT 的可行性。这些数据可用于为 SRM 管理的多中心试验提供信息。患者总结:我们评估了患有小肾肿瘤的患者是否会同意一项比较两种不同治疗方法的试验:冷冻消融(通过皮肤穿过小针来冷冻肾肿瘤)和切除部分肾脏的手术。我们发现大多数患者都同意,因此全面的试验是可行的。

相似文献

1
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.保肾治疗(NEST)小肾肿瘤:经皮冷冻消融与机器人辅助部分肾切除术比较的可行性队列嵌入式随机对照试验。
Eur Urol. 2024 Apr;85(4):333-336. doi: 10.1016/j.eururo.2023.07.012. Epub 2023 Sep 9.
2
Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing phron paring reatment (NEST) for small renal masses.小肾肿瘤患者实施 phron paring 治疗(NEST)的队列嵌入式随机对照试验可行性研究方案。
BMJ Open. 2019 Jun 11;9(6):e030965. doi: 10.1136/bmjopen-2019-030965.
3
Robot-assisted partial nephrectomy vs laparoscopic cryoablation for the small renal mass: redefining the minimally invasive 'gold standard'.机器人辅助部分肾切除术与腹腔镜冷冻消融术治疗小肾肿瘤:重新定义微创的“金标准”。
BJU Int. 2014 Jan;113(1):92-9. doi: 10.1111/bju.12252. Epub 2013 Oct 31.
4
Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation.75 岁以上患者 T1 期肾细胞癌的微创保肾治疗:机器人辅助部分肾切除术与经皮消融术治疗效果比较。
Eur Radiol. 2023 Dec;33(12):8426-8435. doi: 10.1007/s00330-023-09975-5. Epub 2023 Jul 19.
5
Percutaneous Cryoablation versus Robot-Assisted Partial Nephrectomy of Renal T1A Tumors: a Single-Center Retrospective Cost-Effectiveness Analysis.经皮冷冻消融与机器人辅助部分肾切除术治疗 T1A 期肾肿瘤:单中心回顾性成本效益分析。
Cardiovasc Intervent Radiol. 2021 Jun;44(6):892-900. doi: 10.1007/s00270-020-02732-x. Epub 2021 Jan 3.
6
A multi-institutional report of peri-operative and functional outcomes after robot-assisted partial nephrectomy in patients with a solitary kidney.多机构报告机器人辅助部分肾切除术在孤立肾患者中的围手术期和功能结果。
J Robot Surg. 2019 Jun;13(3):423-428. doi: 10.1007/s11701-018-0883-5. Epub 2018 Oct 12.
7
Percutaneous cryoablation for recurrent low grade renal cell carcinoma after failed nephron-sparing surgery.保留肾单位手术失败后复发性低级别肾细胞癌的经皮冷冻消融术
Can J Urol. 2013 Oct;20(5):6933-7.
8
Robotic partial nephrectomy versus laparoscopic cryoablation for the small renal mass.机器人辅助部分肾切除术与腹腔镜冷冻消融术治疗小肾肿瘤的比较。
Eur Urol. 2012 May;61(5):899-904. doi: 10.1016/j.eururo.2012.01.007. Epub 2012 Jan 14.
9
Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: the ROPARN study.腹膜后与经腹机器人辅助部分肾切除术的随机对照可行性试验:ROPARN研究
BJU Int. 2025 Jun;135(6):977-986. doi: 10.1111/bju.16653. Epub 2025 Jan 22.
10
Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for Renal Cell Carcinoma.经腹腔机器人辅助部分肾切除术治疗肾细胞癌的 5 年肿瘤学结果。
Eur Urol. 2016 Jun;69(6):1149-54. doi: 10.1016/j.eururo.2015.12.004. Epub 2015 Dec 22.

引用本文的文献

1
Percutaneous Image-Guided Ablation of Renal Cancer: Traditional and Emerging Indications, Energy Sources, Techniques, and Future Developments.经皮影像引导下的肾癌消融:传统与新出现的适应证、能量来源、技术及未来发展
Medicina (Kaunas). 2025 Feb 28;61(3):438. doi: 10.3390/medicina61030438.
2
Image-guided percutaneous ablative treatments for renal cell carcinoma.影像引导下经皮肾细胞癌消融治疗
Eur Radiol. 2025 Mar 7. doi: 10.1007/s00330-025-11480-w.
3
Transabdominal Robotic-Assisted Partial Nephrectomy and CT-Guided Percutaneous Cryoablation for the Treatment of De Novo Kidney Tumors After Liver Transplantation.
经腹机器人辅助部分肾切除术及CT引导下经皮冷冻消融术治疗肝移植术后新发肾肿瘤
Life (Basel). 2025 Feb 7;15(2):254. doi: 10.3390/life15020254.
4
Percutaneous Cryotherapy and Radiofrequency Ablation of Renal Masses: Multicenter Comparative Analysis with Minimum 3-Year Follow-up.经皮冷冻治疗与射频消融肾肿物:至少3年随访的多中心比较分析
Int Braz J Urol. 2025 Mar-Apr;51(2). doi: 10.1590/S1677-5538.IBJU.2024.0565.
5
Clinical value of contrast-enhanced ultrasound combined with quantitative analysis in Bosniak ≥ II cystic renal masses.超声造影联合定量分析在Bosniak≥II级囊性肾肿块中的临床价值
Abdom Radiol (NY). 2024 Dec 18. doi: 10.1007/s00261-024-04744-4.
6
Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.经皮消融与微创部分肾切除术治疗 T1 期肾癌的围手术期、功能和肿瘤学结局:汇总分析结果。
J Robot Surg. 2024 Aug 6;18(1):306. doi: 10.1007/s11701-024-02052-z.
7
Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes.经皮消融与机器人辅助部分肾切除术治疗 cT1 期肾细胞癌:比较结局的循证分析。
J Robot Surg. 2024 Jul 30;18(1):301. doi: 10.1007/s11701-024-02037-y.
8
Image-Guided Ablation of Renal Masses: Challenges to Produce High-Quality Evidence and Future Directions.图像引导下肾肿块消融:生成高质量证据面临的挑战及未来方向
Semin Intervent Radiol. 2024 Jul 10;41(2):144-153. doi: 10.1055/s-0044-1787163. eCollection 2024 Apr.
9
Reconsidering nephron-sparing strategies for the management of small renal tumors: a call for the inclusion of level 1 evidence in the debate.重新审视保留肾单位策略在小肾肿瘤管理中的应用:呼吁在辩论中纳入一级证据
Transl Androl Urol. 2024 Jun 30;13(6):1049-1052. doi: 10.21037/tau-23-661. Epub 2024 Jun 11.
10
Management of small renal mass: unmet needs and quest for high quality evidence.小肾肿瘤的管理:未满足的需求与对高质量证据的探寻
Transl Androl Urol. 2024 Apr 30;13(4):643-646. doi: 10.21037/tau-23-651. Epub 2024 Apr 7.